Products
Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-729
Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 211, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc.,[1] the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.
Alefacept is a recombinant Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Alefacept is used to treat moderate to severe plaque psoriasis. It Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-729-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-729-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-729-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-729-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11 |
| INN Name | Alefacept |
| Target | CD2 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [CD58 (LFA3, lymphocyte function associated antigen 3)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [CD58 (LFA3, lymphocyte function associated antigen 3)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Astellas Pharma US, Inc. (Northbrook IL USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
